E-cadherin免疫组化在乳腺癌分型中常规应用的随机诊断研究
该随机诊断研究由5位乳腺病理专家对1001例乳腺癌活检或切除标本进行分型,比较先HE后E-cadherin与直接HE联合E-cadherin两种流程。结果显示常规E-cadherin免疫组化可降低分型不确定性并提高准确性,但存在额外免疫染色冗余及E-cadherin阳性浸润性小叶癌仍难以确诊的问题。
要点
- 常规E-cadherin免疫组化可降低乳腺癌分型不确定性并提高准确性。
- E-cadherin阳性浸润性小叶癌仍可能导致分型困难,尤其生长模式不典型时。
- 常规使用可能带来冗余的额外免疫染色。
核心结论
- 常规E-cadherin免疫组化可降低分型不确定性并提高分型准确性,但代价是可能冗余的额外免疫染色。
- 该流程不能排除E-cadherin阳性浸润性小叶癌所致的不确定性,尤其生长模式不典型时难以 confident 标注为浸润性小叶癌。
研究设计与样本
- 随机诊断研究,5位有乳腺病理经验的病理学家来自4家匈牙利机构。
- 1001例乳腺癌来自诊断性粗针活检或切除标本,随机分配至先HE诊断后E-cadherin免疫组化组或直接HE联合E-cadherin诊断组。
主要发现
- HE诊断组524例中73例(14%)被判定为不确定。
- E-cadherin使524例中14例(2.7%)初始组织学类型改变,包括3例HE基于自信分型者。
- 直接双重评估组477例中88例(18%)认为E-cadherin免疫染色有用,分型不确定性降至5%(25/477例),但未为零。
- 171例不确定、困难、非典型病例集体评估后多数达成共识诊断,但15例组织学类型仍存疑。
- 13例尝试CDH1基因测序并成功,7例发现致病性遗传变异。
临床怎么用
- 在乳腺癌分型中常规使用E-cadherin免疫组化可减少不确定性并提高准确性。
- 需注意E-cadherin阳性浸润性小叶癌仍可能造成分型困难,尤其生长模式不典型时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Invasive lobular carcinoma (ILC) has distinct morphology and association with loss of E-cadherin function. It has special clinical and imaging features, and its proper recognition is important. Following a recent proposal, we tested the value of the routine use of E-cadherin immunohistochemistry (IHC) in recognizing ILC. METHODS AND RESULTS: Five pathologists with experience in breast pathology from four Hungarian institutions histotyped 1001 breast cancers from diagnostic core biopsies or excision specimens randomly assigned to haematoxylin and eosin (HE) diagnosis first, followed by E-cadherin IHC; or to immediate HE and E-cadherin-based diagnosis. Of 524 cases with HE diagnosis, 73(14%) were deemed uncertain. E-cadherin made the initial histological type change in 14/524 cases (2.7%), including three with confident HE-based type allocation. Use of E-cadherin immunostaining was considered useful in 88/477 cases (18%) with immediate dual assessment, and typing uncertainty went down to 5% (25/477 cases), but was not zero. Collective assessment of 171 uncertain, difficult, nonclassical cases resulted in consensus diagnosis in most cases, but 15 cases were still doubtful as concerns their proper histological type. CDH1 gene sequencing was attempted and successful in 13; pathogenic genetic alterations were identified in seven cases. CONCLUSIONS: The routine use of E-cadherin IHC decreases the uncertainty in typing and improves the typing accuracy at the cost of potentially redundant additional immunostains. Furthermore, this procedure does not exclude uncertainty due to E-cadherin-positive ILCs, which are occasionally difficult to confidently label as ILC, especially when the growth pattern is not classic.
引用
- Cserni G, Kálmán E, Udvarhelyi N, et al. Evaluation of the routine use of E-cadherin immunohistochemistry in the typing of breast carcinomas: results of a randomized diagnostic study. Histopathology. 2023. PMID: 37609779. doi:10.1111/his.15026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。